Treatment Response Time

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 223830 Experts worldwide ranked by ideXlab platform

Yi Ting Yen - One of the best experts on this subject based on the ideXlab platform.

  • radiation dose escalation can improve local disease control and survival among esophageal cancer patients with large primary tumor volume receiving definitive chemoradiotherapy
    PLOS ONE, 2020
    Co-Authors: Forn Chia Lin, Wei Lun Chang, Nai Jung Chiang, Meng Ying Lin, Ta Jung Chung, Tzu Hui Pao, Wu Wei Lai, Yau Lin Tseng, Yi Ting Yen
    Abstract:

    Background This study aimed to investigate the correlation between primary tumor volume and cancer failure patterns in esophageal squamous cell carcinoma (ESCC) treated with definitive concurrent chemoradiotherapy (CCRT) and examine whether increasing radiation dose can improve the outcome. Methods We retrospectively reviewed 124 patients with stage III ESCC treated by definitive CCRT. The primary tumor volume calculated from the radiotherapy planning computed tomography scans was correlated to Treatment Response, Time to disease progression, and overall survival. We further analyzed whether a higher radiation dose correlated with better disease control and patient survival. Results Patients with poor CCRT Response had a larger primary tumor volume than those with good Response (97.9 vs 64.3 cm3, P = 0.032). The optimal cutoff value to predict CCRT Response was 55.3 cm3. Large primary tumor volume (≥ 55.3 cm3) correlated with shorter Time to tumor progression in the esophagus (13.6 vs 48.6 months, P = 0.033) compared with small tumor volume ( 60 gray significantly prolonged the Time to tumor progression in esophagus (20.3 vs 10.1 months, P = 0.036) and overall survival (12.2 vs 8.0 months, P = 0.030), compared with dose ≤ 60 gray. In contrast, higher radiation dose did not benefit local disease control or overall survival in the small esophageal tumors (< 55.3 cm3). Conclusion Large primary tumor volume correlates with poor local control and overall survival in ESCC treated with definitive CCRT. Radiation dose > 60 gray can improve the outcomes in patients with large primary tumor. Further prospective dose escalation trials are warranted.

Nai Jung Chiang - One of the best experts on this subject based on the ideXlab platform.

  • radiation dose escalation can improve local disease control and survival among esophageal cancer patients with large primary tumor volume receiving definitive chemoradiotherapy
    PLOS ONE, 2020
    Co-Authors: Forn Chia Lin, Wei Lun Chang, Nai Jung Chiang, Meng Ying Lin, Ta Jung Chung, Tzu Hui Pao, Wu Wei Lai, Yau Lin Tseng, Yi Ting Yen
    Abstract:

    Background This study aimed to investigate the correlation between primary tumor volume and cancer failure patterns in esophageal squamous cell carcinoma (ESCC) treated with definitive concurrent chemoradiotherapy (CCRT) and examine whether increasing radiation dose can improve the outcome. Methods We retrospectively reviewed 124 patients with stage III ESCC treated by definitive CCRT. The primary tumor volume calculated from the radiotherapy planning computed tomography scans was correlated to Treatment Response, Time to disease progression, and overall survival. We further analyzed whether a higher radiation dose correlated with better disease control and patient survival. Results Patients with poor CCRT Response had a larger primary tumor volume than those with good Response (97.9 vs 64.3 cm3, P = 0.032). The optimal cutoff value to predict CCRT Response was 55.3 cm3. Large primary tumor volume (≥ 55.3 cm3) correlated with shorter Time to tumor progression in the esophagus (13.6 vs 48.6 months, P = 0.033) compared with small tumor volume ( 60 gray significantly prolonged the Time to tumor progression in esophagus (20.3 vs 10.1 months, P = 0.036) and overall survival (12.2 vs 8.0 months, P = 0.030), compared with dose ≤ 60 gray. In contrast, higher radiation dose did not benefit local disease control or overall survival in the small esophageal tumors (< 55.3 cm3). Conclusion Large primary tumor volume correlates with poor local control and overall survival in ESCC treated with definitive CCRT. Radiation dose > 60 gray can improve the outcomes in patients with large primary tumor. Further prospective dose escalation trials are warranted.

Forn Chia Lin - One of the best experts on this subject based on the ideXlab platform.

  • radiation dose escalation can improve local disease control and survival among esophageal cancer patients with large primary tumor volume receiving definitive chemoradiotherapy
    PLOS ONE, 2020
    Co-Authors: Forn Chia Lin, Wei Lun Chang, Nai Jung Chiang, Meng Ying Lin, Ta Jung Chung, Tzu Hui Pao, Wu Wei Lai, Yau Lin Tseng, Yi Ting Yen
    Abstract:

    Background This study aimed to investigate the correlation between primary tumor volume and cancer failure patterns in esophageal squamous cell carcinoma (ESCC) treated with definitive concurrent chemoradiotherapy (CCRT) and examine whether increasing radiation dose can improve the outcome. Methods We retrospectively reviewed 124 patients with stage III ESCC treated by definitive CCRT. The primary tumor volume calculated from the radiotherapy planning computed tomography scans was correlated to Treatment Response, Time to disease progression, and overall survival. We further analyzed whether a higher radiation dose correlated with better disease control and patient survival. Results Patients with poor CCRT Response had a larger primary tumor volume than those with good Response (97.9 vs 64.3 cm3, P = 0.032). The optimal cutoff value to predict CCRT Response was 55.3 cm3. Large primary tumor volume (≥ 55.3 cm3) correlated with shorter Time to tumor progression in the esophagus (13.6 vs 48.6 months, P = 0.033) compared with small tumor volume ( 60 gray significantly prolonged the Time to tumor progression in esophagus (20.3 vs 10.1 months, P = 0.036) and overall survival (12.2 vs 8.0 months, P = 0.030), compared with dose ≤ 60 gray. In contrast, higher radiation dose did not benefit local disease control or overall survival in the small esophageal tumors (< 55.3 cm3). Conclusion Large primary tumor volume correlates with poor local control and overall survival in ESCC treated with definitive CCRT. Radiation dose > 60 gray can improve the outcomes in patients with large primary tumor. Further prospective dose escalation trials are warranted.

Meng Ying Lin - One of the best experts on this subject based on the ideXlab platform.

  • radiation dose escalation can improve local disease control and survival among esophageal cancer patients with large primary tumor volume receiving definitive chemoradiotherapy
    PLOS ONE, 2020
    Co-Authors: Forn Chia Lin, Wei Lun Chang, Nai Jung Chiang, Meng Ying Lin, Ta Jung Chung, Tzu Hui Pao, Wu Wei Lai, Yau Lin Tseng, Yi Ting Yen
    Abstract:

    Background This study aimed to investigate the correlation between primary tumor volume and cancer failure patterns in esophageal squamous cell carcinoma (ESCC) treated with definitive concurrent chemoradiotherapy (CCRT) and examine whether increasing radiation dose can improve the outcome. Methods We retrospectively reviewed 124 patients with stage III ESCC treated by definitive CCRT. The primary tumor volume calculated from the radiotherapy planning computed tomography scans was correlated to Treatment Response, Time to disease progression, and overall survival. We further analyzed whether a higher radiation dose correlated with better disease control and patient survival. Results Patients with poor CCRT Response had a larger primary tumor volume than those with good Response (97.9 vs 64.3 cm3, P = 0.032). The optimal cutoff value to predict CCRT Response was 55.3 cm3. Large primary tumor volume (≥ 55.3 cm3) correlated with shorter Time to tumor progression in the esophagus (13.6 vs 48.6 months, P = 0.033) compared with small tumor volume ( 60 gray significantly prolonged the Time to tumor progression in esophagus (20.3 vs 10.1 months, P = 0.036) and overall survival (12.2 vs 8.0 months, P = 0.030), compared with dose ≤ 60 gray. In contrast, higher radiation dose did not benefit local disease control or overall survival in the small esophageal tumors (< 55.3 cm3). Conclusion Large primary tumor volume correlates with poor local control and overall survival in ESCC treated with definitive CCRT. Radiation dose > 60 gray can improve the outcomes in patients with large primary tumor. Further prospective dose escalation trials are warranted.

Ta Jung Chung - One of the best experts on this subject based on the ideXlab platform.

  • radiation dose escalation can improve local disease control and survival among esophageal cancer patients with large primary tumor volume receiving definitive chemoradiotherapy
    PLOS ONE, 2020
    Co-Authors: Forn Chia Lin, Wei Lun Chang, Nai Jung Chiang, Meng Ying Lin, Ta Jung Chung, Tzu Hui Pao, Wu Wei Lai, Yau Lin Tseng, Yi Ting Yen
    Abstract:

    Background This study aimed to investigate the correlation between primary tumor volume and cancer failure patterns in esophageal squamous cell carcinoma (ESCC) treated with definitive concurrent chemoradiotherapy (CCRT) and examine whether increasing radiation dose can improve the outcome. Methods We retrospectively reviewed 124 patients with stage III ESCC treated by definitive CCRT. The primary tumor volume calculated from the radiotherapy planning computed tomography scans was correlated to Treatment Response, Time to disease progression, and overall survival. We further analyzed whether a higher radiation dose correlated with better disease control and patient survival. Results Patients with poor CCRT Response had a larger primary tumor volume than those with good Response (97.9 vs 64.3 cm3, P = 0.032). The optimal cutoff value to predict CCRT Response was 55.3 cm3. Large primary tumor volume (≥ 55.3 cm3) correlated with shorter Time to tumor progression in the esophagus (13.6 vs 48.6 months, P = 0.033) compared with small tumor volume ( 60 gray significantly prolonged the Time to tumor progression in esophagus (20.3 vs 10.1 months, P = 0.036) and overall survival (12.2 vs 8.0 months, P = 0.030), compared with dose ≤ 60 gray. In contrast, higher radiation dose did not benefit local disease control or overall survival in the small esophageal tumors (< 55.3 cm3). Conclusion Large primary tumor volume correlates with poor local control and overall survival in ESCC treated with definitive CCRT. Radiation dose > 60 gray can improve the outcomes in patients with large primary tumor. Further prospective dose escalation trials are warranted.